Highlights for January 2017
Incyte pays $53M upfront for Calithera I-O drug, setting stage for anti-PD-1 combo trials in solid tumors.
- Celgene is jumping on the M&A bandwagon with a $775 million biobucks deal for Delinia, which only had its Series A last September.
- Merck commit to €240 million ($258 million) in milestones to bag Domain Therapeutics’ next-generation adenosine receptor program.
- Enteris BioPharma signs oral diabetes pact with Sanofi.
- GeoVax draws a bead on hep B with therapeutic vaccine deal.
- Maryland biotechs PharmAthene and Novartis-backed Altimmune pen merger deal.
- Takeda and NY biotech Ovid ink rare drug development pact.
- Lilly buys migraine biotech CoLucid, and the drug it outlicensed, for $960M.
- Merck Licenses four oncology R&D programs from Vertex.
- OmniActive Health buys 85% stake in fragrance firm Indfrag for $80 million.
- RedHill Biopharma announces exclusive US co-promotion agreement with Concordia for GI drug Donnatal.
- Aurobindo Pharma buys Generis in a bid to boost margins in Europe.
For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.